Company news

Arvinas, Inc. news in 2026

Arvinas, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation

October 27, 2026

Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026

October 27, 2026

Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease

October 7, 2026

Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®

October 1, 2026

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 29, 2026

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate

September 29, 2026

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

September 28, 2026

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 1, 2026

Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 4, 2026

Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026

July 28, 2026

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

June 3, 2026

Arvinas Employees Give Back During Company-wide Impact Day

May 18, 2026

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 12, 2026

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

May 12, 2026

Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

May 5, 2026

Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

May 4, 2026

Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

April 30, 2026

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days

March 17, 2026

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

March 11, 2026

Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 23, 2026

Initial Statement of Beneficial Ownership (Form 3)

February 18, 2026

Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

February 17, 2026

Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director

February 12, 2026

Calls in 2026

Decks in 2026